Madrigal Pharmaceuticals (NASDAQ:MDGL) stock declined 4% in pre-market trading Monday after the FDA approved Novo Nordisk’s (NYSE:NVO) Wegovy for treating adults with noncirrhotic metabolic ...

We've got a prize package that will transport you back to the 80s, 90s or Y2K with a stay at Butlin's for one of its ...

U.S. stock futures are ticking lower after indexes finished higher for a second straight week. Investors are looking ahead this week to key remarks from Fed Chair Jerome Powell and a string of ...

The FTSE 100 and European markets were lower by noon on Monday as Ukrainian president Volodymyr Zelensky and a handful of ...

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

The drug received accelerated approval for use in patients with metabolic dysfunction-associated steatohepatitis (MASH).

The Slimming World plan allows members to enjoy numerous "free" foods including meat, pasta, rice and the majority of fruit ...

Novo Nordisk's shares saw an uptick following the FDA's approval of Wegovy, its flagship drug, to treat a severe fatty liver disease.

Shares in Novo Nordisk rose as much as 5% in early European trading Monday, regaining some ground after losing more than half of their value over the past year.

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

Copenhagen-listed shares in pharmaceuticals giant Novo Nordisk rose nearly 4% on Monday morning, after the company announced ...